安德克萨内特阿尔法与PCC产品对于XA因子抑制剂出血:一个系统性审查与元分析
C Michael White1,2, Kimberly Snow Caroti1,2, Youssef Bessada1
1University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.
Pharmacotherapy
|May 9, 2024
概括
与XA因子抑制剂相关出血相比,安德克萨内特阿尔法 (AA) 显示出优异的静血疗效和降低的死亡率与前热血素复合物缩剂 (PCC) 相比. 这一系统性审查突出了AAAA的重点.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 血液学 血液学 血液学
- 临床研究方法论 临床研究方法论
背景情况:
- 与Xa因子抑制剂 (FXaI) 相关的大型出血是一个重大的临床挑战.
- 之前对安德克萨内特阿尔法 (AA) 和前素复合缩物 (PCC) 的元分析缺乏最近的数据和偏差风险评估.
- 对FXaI相关出血的AA与PCC的比较有效性需要进行最新的评估.
研究的目的:
- 系统地审查和元分析与PCC相比AA对FXaI相关重大出血的有效性.
- 评估研究偏差风险对AA和PCC的比较有效性的影响.
- 评估与AA相比PCC相关的静血疗效,死亡率和血栓事件.
主要方法:
- 通过PubMed和Embase识别的比较研究的系统综述和随机效应元分析.
- 使用非随机研究方法指数 (MINORS) 和JBI批判性评估工具评估偏差风险.
- 对偏见低中度和高风险的研究分别进行了元分析,并结合了.
主要成果:
- 低中等风险偏差研究表明,AA改善了静血疗效 (OR 2.72) 和降低了住院 (OR 0.48) 和30天死亡率 (OR 0.49),而不是PCC.
- 包括所有研究在内的聚合分析显示,AA与PCC相比,AA改善了静血疗效 (OR 1.36) 和降低了30天死亡率 (OR 0.53).
- 在偏差风险组中,在AA和PCC之间没有观察到血栓事件的统计学上显著差异.
结论:
- 来自中低质量的研究的证据表明,安德克萨内特阿尔法 (AA) 在FXaI相关出血方面优于前热血素复合缩物 (PCC).
- 与PCC相比,AA显示出增强的静血疗效和降低的死亡结果.
- 无论偏差如何,汇集的数据都支持AA对PCC在血液静止和死亡率降低方面的效率提高.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
686
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
686
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
521
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
521
Coagulation
6.3K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.3K


